[The cyclophosphamide treatment of glomerulonephritis patients].
An analysis is presented of direct results of monotherapy with cyclophosphamide of 70 patients suffering of acute and chronic glomerulonephritis. The treatment proved effective in 10% of patients. It was established that the initially reduced levels of immunoglobulins G and A in the blood serum of patients with glomerulonephritis are a prognosis-positive factor for the use of cyclophosphamide.
Dorets'kyĭ
V V
VV
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004341:Drug Evaluation; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000276:immunology
D003520:Cyclophosphamide
Likuvannia khvorykh na hlomerulonefrit tsyklofosfamidom.